Full Text View
Tabular View
Study Results
Related Studies
Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)
This study has been completed.
Study NCT00233064   Information provided by MedImmune LLC
First Received: October 3, 2005   Last Updated: March 27, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Lung Disease
Additional conditions recognized in this trial
Lung Diseases
More general conditions related to this trial
Respiratory Tract Diseases
Interventions listed in this trial
Lyophilized Palivizumab
Liquid Palivizumab
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Palivizumab
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
MedImmune LLC


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services